title: [Some aspects of erectile dysfunction pathogenesis and treatment in patients with obesity].
authors.forename: A S
authors.initials: AS
authors.lastname: Ametov
authors.forename: O V
authors.initials: OV
authors.lastname: Teodorovich
authors.forename: L V
authors.initials: LV
authors.lastname: Kondrat'eva
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Popova
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D004730:Endothelium, Vascular / Q000503:physiopathology; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology; D009765:Obesity / Q000150:complications* / Q000201:enzymology; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000187:drug effects; D012307:Risk Factors; D014664:Vasodilation / Q000502:physiology
chemical_list: D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human